Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details Textual)

v3.3.0.814
Commitments and Contingencies (Details Textual)
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Feb. 27, 2014
USD ($)
Sep. 30, 2015
USD ($)
Apr. 22, 2014
USD ($)
Aug. 28, 2012
USD ($)
patients
Jul. 24, 2012
USD ($)
Jun. 15, 2012
USD ($)
Sep. 30, 2015
USD ($)
Sep. 30, 2014
USD ($)
Sep. 30, 2015
USD ($)
Sep. 30, 2014
USD ($)
Dec. 31, 2014
USD ($)
Dec. 31, 2012
USD ($)
Dec. 31, 2007
USD ($)
Commitments and Contingencies (Textual)                          
Research recorded fees             $ 2,828,093 $ 4,141,390 $ 10,714,766 $ 7,861,790      
Letter of credit     $ 34,733                    
Lease agreement description                
On April 22, 2014, the Company entered into a sublease agreement for office space located at 379 Thornall Street, Edison, NJ. This agreement expires on September 30, 2016. The Company issued a letter of credit for $34,733 to the existing tenant and maintained a $34,733 certified deposit as collateral for the letter of credit.
        
Manufacturing Agreement [Member]                          
Commitments and Contingencies (Textual)                          
Project estimated cost for clinical trials of drug Ac-225-HuM195 $ 1,700,000                        
Non - refundable institutional fee 562,790                        
Total project estimated to cost $ 5,000,000                        
Research and development costs                 $ 100,000   $ 800,000    
Amount paid to goodwin                 3,900,000 2,000,000      
Research Agreement [Member]                          
Commitments and Contingencies (Textual)                          
Research recorded fees   $ 146,713             55,000 0      
Total project estimated to cost               183,391   183,391      
Abbview Biotherapeutics Corp [Member] | Product Development and Patent License Agreement [Member]                          
Commitments and Contingencies (Textual)                          
License fee payment                 3,000,000        
Milestones payments                 $ 7,750,000        
Description of royalty payment                 The Company shall pay to AbbVie Biotherapeutics Corp. on a country-by-country basis a royalty of 12% of net sales of all licensed products until the later of: (1) 12.5 years after the first commercial sale, or (2) when the patents expire.        
Royalty of net sales percentage                 12.00%        
Abbview Biotherapeutics Corp [Member] | After First Net Sales [Member]                          
Commitments and Contingencies (Textual)                          
Milestones payments                 $ 1,500,000        
Abbview Biotherapeutics Corp [Member] | Phase 1 Clinical Trial of a licensed product [Member]                          
Commitments and Contingencies (Textual)                          
Milestones payments         $ 750,000       750,000        
Abbott Biotherapeutics Corp [Member] | After First Net Sales [Member] | Product Development and Patent License Agreement [Member]                          
Commitments and Contingencies (Textual)                          
Net sales in milestones payment                 $ 10,000,000        
Aptiv Solutions [Member]                          
Commitments and Contingencies (Textual)                          
Down payment of project estimated cost percentage                 12.50%        
Down payment for project                 $ 1,900,000     $ 239,000 $ 239,000
Accrued expenses   500,000         500,000 300,000 500,000 300,000      
Total project estimated to cost   2,700,000         2,700,000   2,700,000        
Fred Hutchinson Cancer Research Center [Member] | license and sponsored research agreement [Member]                          
Commitments and Contingencies (Textual)                          
Milestones payments           $ 1,000,000              
Description of royalty payment           Royalty payments of 2% of net sales will be due to FHCRC.              
Fund for Fred Hutchinson Cancer Research Center lab ( Per year for the first two years )           $ 150,000              
Fund for Fred Hutchinson Cancer Research Center lab ( thereafter )           250,000              
Accrued expenses   $ 200,000         $ 200,000 100,000 $ 200,000 100,000      
Fred Hutchinson Cancer Research Center [Member] | Maximum [Member] | license and sponsored research agreement [Member]                          
Commitments and Contingencies (Textual)                          
Clinical trial cost for approval of food and drug administration           23,500,000              
Fred Hutchinson Cancer Research Center [Member] | Minimum [Member] | license and sponsored research agreement [Member]                          
Commitments and Contingencies (Textual)                          
Clinical trial cost for approval of food and drug administration           $ 13,200,000              
University of Texas M.D. Anderson Cancer Center [Member] | Clinical Trial Agreement [Member]                          
Commitments and Contingencies (Textual)                          
Number of Patients | patients       24                  
Start-up fee for clinical trial       $ 33,946                  
Non - refundable institutional fee       14,500                  
Total project estimated to cost       $ 500,000                  
Clinical trial expense               $ 100,000   $ 100,000